←
David Su246 posts
David Su avatar

David Su

@DavidSuMD

Incoming surg onc fellow @COH_SurgOnc @YaleSurgRes. Father, husband, dog dad. Ideas my own.

◷ Joined May 2014▧ 11 Photos and videos
Patrick Hsu avatar
⟳ David Su retweeted
Patrick Hsu@pdhsu·Oct 7

Honored to be alongside so many amazing colleagues and grateful to my lab and mentors for their partnership and inspiration. This is for them, and for fundamental research

Announcing the 2026 National Laureates of the @Blavatnikawards, tonight each will receive $250,000 at the 20th Anniversary Gala: 🧪David Nagib @Nagiblab @OhioState, 🧬Patrick Hsu @pdhsu @ArcInstitute @Stanford, ⚡Jonathan Rivnay @jrivnay @NorthwesternU blavatnikawards.org/news/ite…

Post attachment
The Nobel Prize avatar
⟳ David Su retweeted
The Nobel Prize@NobelPrize·Oct 5

BREAKING NEWS The 2026 #NobelPrize in Physiology or Medicine has been awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel “for their discoveries concerning light-gated ion channels and optogenetics.”

Post attachment
Zhi Ven Fong, MD MPH DrPH avatar
⟳ David Su retweeted
Zhi Ven Fong, MD MPH DrPH@ZhiVenFongMD·Sep 4

53min 🤖 Whipple resection in a straight forward case, sped up 4x unedited 👇🏻 youtu.be/Cq5z1A9Wy18?is=MFIT… IMO the SMA-first approach with specimen hanging left is the hack. Deal with the uncinate as step 1 while you’re fresh & uncinate not congested. C&C welcomed. Short version:

2:47
David Su avatar
David Su@DavidSuMD·Aug 21

Impressive Phase III results on personalized mRNA vaccines +IT in ⬆️ RFS and DMFS in stage IIB-IV melanoma. Justifies the stock surge but Qs remain: - how do we improve neoAg prediction? - reproducible in immunologically cold cancers? - sequencing vaccines w neoadjuvant IT?

Moderna just became the first company in history to pass a Phase 3 trial with a personalized cancer vaccine. Every single dose is a different drug. Here's how it works. Surgeons remove the melanoma, then sequence the tumor's DNA and RNA. An algorithm compares it against the patient's healthy cells and picks up to 34 mutations unique to that one person's cancer. Those mutations get encoded into a custom mRNA strand, wrapped in lipid nanoparticles, and injected. The immune system reads the code, learns what that specific tumor looks like, and hunts down whatever cells surgery missed. Paired with Keytruda, which releases the brakes on T cells, the earlier trial showed a 49% cut in recurrence risk that held steady from year 3 all the way to year 5. The manufacturing is what pharma people can't stop thinking about. Drug factories are built to stamp out identical pills by the billion. This requires designing, synthesizing, and quality-testing a brand new drug for every patient, in weeks, from biopsy to injection. A batch size of one. Scientists have chased therapeutic cancer vaccines for 40 years. A handful got approved. None were mRNA, and none were built per patient. The Phase 3 covered 1,137 melanoma patients. Nine more trials are already running in lung, bladder, kidney, pancreatic, and gastric cancer. Moderna was worth $25 billion yesterday, down more than 85% from its COVID peak. Wall Street had priced mRNA as a one-pandemic technology. The repricing took one morning.

Siyuan (Steven) Wang avatar
⟳ David Su retweeted
Siyuan (Steven) Wang@SStevenWang·Aug 19

Glad to co-organize the Cold Spring Harbor Asia Meeting: Frontiers in Single-Cell & Spatial Omics (Oct 19-23). Abstract deadline Sept 4, 2026. Looking forward to seeing you near the beautiful Dushu Lake in Suzhou this fall! Meeting website: csh-asia.org/?content/3118

Post attachment
Arc Institute avatar
⟳ David Su retweeted
Arc Institute@arcinstitute·Jun 23

The future of biology is agentic. We're proud to work with NVIDIA on the Evo series of models and are excited to see the NVIDIA BioNeMo Agent Toolkit launch to accelerate programmable biology.

Science is entering a new era - one where AI agents can do scientific work. 🧬 Today NVIDIA is launching the BioNeMo Agent Toolkit - an open, agent-ready toolkit that gives any AI agent callable tools for protein structure prediction, molecular docking, generative chemistry, genomic analysis, and more. (1/2)

0:36
Nate Krah avatar
⟳ David Su retweeted
Nate Krah@N8Krah·May 6

🧬 New paper out in @Nature! We used CRISPR to selectively kill cancer cells based on a single-letter mutation in their RNA. The story I want to highlight: KRAS — one of the most notorious drivers of human cancer. A short thread on what we found 🧵

Aaron Newman Lab avatar
⟳ David Su retweeted
Aaron Newman Lab@AaronNewmanLab·May 6

1/ Thrilled to share our new paper, out today in @Nature: "Non-invasive profiling of the tumour microenvironment with spatial ecotypes". Paper (open access): nature.com/articles/s41586-0…

Gavitt Woodard avatar
⟳ David Su retweeted
Gavitt Woodard@GavittWoodard·Mar 27

Dartmouth is so lucky to have you @DrRoyHerbst! Thank you for your 15 years of Thoracic Oncology and SPORE leadership at Yale! You have been such a wonderful mentor and supporter, we will miss you!!

I am honored and excited to announce that I will join the Dartmouth community in July as Director of the Dartmouth Cancer Center. Looking forward to continuing the important work of advancing cancer care, research, and patient impact. @DartmouthCancer @GeiselMed geiselmed.dartmouth.edu/news…

Yale Cancer Center avatar
⟳ David Su retweeted
Yale Cancer Center@YaleCancer·Mar 21

The highest honor bestowed within our organization, the Yale Cancer Center Lifetime Achievement Award, was presented to Dr. Mario Sznol @MSznol by @DrRoyHerbstYale. Dr. Sznol was recognized for 40+ years of extraordinary contributions to oncology. We are proud to celebrate his remarkable legacy. @SmilowCancer

Post attachment
Yingcheng Charles Wu avatar
⟳ David Su retweeted
Yingcheng Charles Wu@Charles_Y_Wu·Feb 5

Big thanks to @GDemaitre and @TheRobotReport for covering the launch of MedOS! 📄📷 We’re building the future of autonomous science and clinical assistance with an AI-XR-Cobot world model. Proud of the team! therobotreport.com/stanford-…

Zhi Ven Fong, MD MPH DrPH avatar
⟳ David Su retweeted
Zhi Ven Fong, MD MPH DrPH@ZhiVenFongMD·Jan 29

1/ When starting a🤖Whipple program, struggle is always balancing patient selection for safe completion vs⬇️volume w being selective. We asked if it was safe w being liberal w pt selection w a lower threshold to convert for non-progression. Results in🧵! sciencedirect.com/science/ar…

Post attachment